Radiopharm Theranostics
RADX
11 hedge funds and large institutions have $3.67M invested in Radiopharm Theranostics in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.
175% more funds holding
Funds holding: 4 → 11 (+7)
113% more capital invested
Capital invested by funds: $1.73M → $3.67M (+$1.95M)
4.9% more ownership
Funds ownership: 4.02% → 8.91% (+4.9%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HSBC Holdings
London,
United Kingdom
|
+$1.02M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$868K |
| 3 |
VF
Virtu Financial
New York
|
+$77.7K |
| 4 |
Jane Street
New York
|
+$77.1K |
| 5 |
MG
Marex Group
London,
|
+$54.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$20.8K |
RADX Hedge Fund Activity: Q4 2025 in Review
11 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Radiopharm Theranostics (RADX) for Q4 2025, worth a combined $3.67M — up 113% from $1.73M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RADX positions and 0 closed out — a net gain of 7 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was HSBC Holdings, opening a new position worth an estimated $1.02M. The largest seller was UBS Group, cutting an estimated $20.8K.
- 11 institutional investors held Radiopharm Theranostics (RADX) as of Q4 2025, up from 4 in Q3 2025.
- Funds reported $3.67M of Radiopharm Theranostics stock for Q4 2025, up 113% quarter-over-quarter.
- 7 funds opened new Radiopharm Theranostics positions in Q4 2025 and 0 closed out, a net change of +7 holders.
- The largest Radiopharm Theranostics buyer in Q4 2025 was HSBC Holdings, an estimated $1.02M added.
- The largest Radiopharm Theranostics seller in Q4 2025 was UBS Group, an estimated $20.8K sold.
Based on aggregated 13F filings for Q4 2025.